 NEW YORK, July 16, 2021 PRNewswire -- AIkido Pharma Inc. Nasdaq: AIKI AIkido or the Company today provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine. The Company stated: The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level. 